"We are an experienced clinical research company bringing quality care to our community via phase 1-4 trials. People think you are a “guinea pig” if you participate in studies. This is not true as 60% of the medications or devices provided are on the market. You are guaranteed to see a physician, not PA or NP, who has a background that includes Yale University and UCSF. But most importantly, you will be heard here as we care about all those we are honored to treat. We are an appointment only facility."

During the past decade, AB Clinical Trials conducted 8 clinical trials. In the 10-year time frame, 8 clinical trials started and 9 clinical trials were completed, i.e. on average, 112.5% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 3 clinical trials were completed. i.e. 60% of trials that started reached the finish line.

Out of the total clinical trials conducted in "AB Clinical Trials" #1 sponsor was "Eli Lilly and Company" with 2 trials, followed by "Pfizer" with 2 trials sponsored, "Elcelyx Therapeutics, Inc." with 1 trials sponsored, "Gilead Sciences" with 1 trials sponsored and "ImmusanT, Inc." with 1 trials sponsored. Other sponsors include 3 different institutions and companies that sponsored additional 13 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "AB Clinical Trials" #1 collaborator was "National Institute of Allergy and Infectious Diseases (NIAID)" with 2 trials as a collaborator, "Biomedical Advanced Research and Development Authority" with 1 trials as a collaborator and "Sucampo Pharmaceuticals, Inc." with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "AB Clinical Trials" are "Atherosclerotic Cardiovascular Disease" (2 trials), "Cardiovascular Disease" (2 trials), "Autoimmune Diseases" (1 trials), "COVID-19" (1 trials) and "Celiac" (1 trials). Many other conditions were trialed in "AB Clinical Trials" in a lesser frequency.

Most popular intervention types in "AB Clinical Trials" are "Drug" (13 trials) and "Biological" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (12 trials), "bococizumab (PF-04950615)" (2 trials), "Dulaglutide" (1 trials), "Inclisiran sodium 300 mg" (1 trials) and "Insulin Glargine" (1 trials). Other intervention names were less common.

The vast majority of trials in "AB Clinical Trials" are 15 trials for "All" genders.

Currently, there are NaN active trials in "AB Clinical Trials". undefined are not yet recruiting, 3 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 8 completed trials in AB Clinical Trials, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in AB Clinical Trials, 0 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 11 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".